- Home
- GH vs FMS Comparison
GH vs FMS Comparison
Compare GH & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | FMS |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | Germany |
| Employees | N/A | 109698 |
| Industry | Medical Specialities | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 12.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GH | FMS |
|---|---|---|
| Price | $87.33 | $22.59 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 19 | 2 |
| Target Price | ★ $119.79 | $30.00 |
| AVG Volume (30 Days) | ★ 2.1M | 451.4K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.57% |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $982,021,000.00 | N/A |
| Revenue This Year | $33.30 | N/A |
| Revenue Next Year | $28.27 | $3.83 |
| P/E Ratio | ★ N/A | $15.62 |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $36.36 | $20.96 |
| 52 Week High | $120.74 | $30.46 |
Technical Indicators
Market Signals| Indicator | GH | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 45.51 |
| Support Level | $82.33 | $22.50 |
| Resistance Level | $90.28 | $24.02 |
| Average True Range (ATR) | 4.67 | 0.36 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 51.08 | 25.08 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.